Ultra-fractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy
CONCLUSIONS: 26Gy/2 fractions HDR BT provided equivalent BCR with lower toxicity compared to 36.25Gy/5 fractions SABR. Both 2-fraction HBR BT and 5-fraction SABR achieved better BCRs than single dose 19Gy HDR BT. The two-fraction HDR BT schedule should be considered as an important comparator in future clinical trials.PMID:33639192 | DOI:10.1016/j.radonc.2021.02.028
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Yat Man Tsang Hannah Tharmalingam Katherine Belessiotis-Richards Shreya Armstrong Peter Ostler Robert Hughes Roberto Alonzi Peter J Hoskin Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Clinical Trials | Gastroenterology | Prostate Cancer | Radiology | Statistics | Study | Toxicology